This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Becton Dickinson (BDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q2 sales.
Why Becton Dickinson (BDX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?
by Zacks Equity Research
Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Zacks Analyst Blog Highlights Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group
by Zacks Equity Research
Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group are part of top Analyst Blog.
AngioDynamics (ANGO) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in its Med Tech business as well as domestic revenues in third-quarter fiscal 2022.
Bet on These 4 Low-Beta, High-Dividend MedTech Stocks for 2022
by Riya Anand
Stocks like Becton, Dickinson and Company (BDX), Phibro Animal Health (PAHC), McKesson Corporation (MCK) and UnitedHealth Group Inc (UNH) are right picks with strong fundamentals.
Here's How Much a $1000 Investment in Becton Dickinson Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co.
by Zacks Equity Research
Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co. have been included in this Analyst Blog.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and strategic deals.
3 Stocks to Focus on With MedTech M&A Scaling New Heights
by Riya Anand
MedTech stocks like Owens & Minor (OMI), Thermo Fisher (TMO) and Medtronic (MDT) are prudent investment choices given their long-term growth potential with recent M&A deals.
The Zacks Analyst Blog Highlights Berkshire Hathaway, Honeywell, Becton, Dickinson, NXP Semiconductors N.V., and Ecolab
by Zacks Equity Research
Berkshire Hathaway, Honeywell, Becton, Dickinson, NXP Semiconductors N.V., and Ecolab have been included in this Analyst Blog.
Top Research Reports for Berkshire Hathaway, Honeywell International & Becton, Dickinson
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Honeywell International Inc. (HON) and Becton, Dickinson and Company (BDX).
Becton Dickinson (BDX) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
If You Invested $1000 in Becton Dickinson 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
The Zacks Analyst Blog Highlights: Apple Inc., The Walt Disney Company, Broadcom Inc., American Express Co. and Becton, Dickinson and Co
by Zacks Equity Research
TApple Inc., The Walt Disney Company, Broadcom Inc., American Express Co. and Becton, Dickinson and Co. are highlighted in this Analyst Blog.
Top Stock Reports for Apple, Walt Disney & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), The Walt Disney Company (DIS), and Broadcom Inc. (AVGO).
Becton Dickinson (BDX) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
BD (BDX) Beats on Q1 Earnings and Revenues, Raises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 27.27% and 4.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Becton, Dickinson and Company (BDX) Ahead of Earnings?
by Zacks Equity Research
Becton, Dickinson and Company (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in the Pharmaceutical segment.